

13 July 2026

Botanix receives Notice of Allowance for additional US patent covering *Sofdra*® drug substance

Phoenix AZ, 13 July 2026: Commercial dermatology company, Botanix Pharmaceuticals Limited (ABN 70 009 109 755) (ASX:BOT, “Botanix” or “the Company”), is pleased to announce that the United States Patent and Trademark Office (“USPTO”) has issued a Notice of Allowance for a US patent application, Serial No. 17/611,158, ‘CRYSTALLINE FORM OF SOFPIRONIUM BROMIDE AND PREPARATION METHOD THEREOF’, which is directed to commercially relevant intellectual property covering the drug substance for *Sofdra*® (sofpironium), the Company’s FDA-approved treatment for primary axillary hyperhidrosis in adults and pediatric patients nine years of age and older.

The allowed claims are directed to proprietary aspects of sofpironium drug substance technology utilised in the commercial manufacture of *Sofdra*. Upon issuance, the patent is expected to provide Botanix with additional intellectual property protection surrounding *Sofdra* in the United States.

‘Strengthening our intellectual property estate around Sofdra remains an important strategic priority for Botanix,’ said Dr Howie McKibbin, Chief Executive Officer of Botanix. ‘This Notice of Allowance further expands the Company’s US patent portfolio supporting the long-term commercial opportunity for Sofdra and reinforces our commitment to protecting key innovations associated with the product.’

The patent application relates to commercially relevant innovations associated with the sofpironium drug substance and, once issued, will provide additional protections to already issued patents that cover *Sofdra*’s commercial drug substance into May 2040.

Release authorised by

Vince Ippolito

Executive Chairman

About Botanix Pharmaceuticals

Botanix Pharmaceuticals Limited (ASX:BOT) is a dermatology company based in Philadelphia and Phoenix (US), which has received FDA approval for *Sofdra*, its product for the treatment of primary axillary hyperhidrosis. *Sofdra* is the first and only new chemical entity approved by FDA to treat primary axillary hyperhidrosis and presents a novel, safe and effective solution for patients who have lacked treatment options for this socially challenging medical condition.

To learn more, please visit: <http://www.botanixpharma.com/>

For more information, please contact:

General enquiries
 Botanix Pharmaceuticals
 Corporate Communications
 P: [+61 8 6285 0083](tel:+61862850083)
info@botanixpharma.com

Investor and Media Relations
 Jane Morgan Management
 Wilamina Russo
 P: [+61 450 646 609](tel:+61450646609)
wr@janemorganmanagement.com.au

Cautionary Note on Forward-Looking Statements

Forward-looking statements can generally be identified by the use of forward-looking words such as, “expect”, “anticipate”, “likely”, “intend”, “should”, “could”, “may”, “predict”, “plan”, “propose”, “will”, “believe”, “forecast”, “estimate”, “target”, “outlook”, “guidance” and other similar expressions and include, but are not limited to, plans and prospects for the Company, the Company’s strategy, future operations, the expected timing and/or results of regulatory approvals and prospects of commercialising product candidates or research collaborations with its partners, including in Japan, the outcome and effects of *Sofdra* and the market for *Sofdra*. Indications of, and guidance or outlook on, future earnings or financial position or performance are also forward-looking statements. The forward-looking statements contained in this Presentation are not indications, guarantees or predictions of future performance and involve known and unknown risks and uncertainties and other factors, many of which are beyond the control of Botanix, and may involve significant elements of subjective judgement and assumptions as to future events which may or may not be correct. Investors should consider the forward-looking statements contained in this Presentation in light of those disclosures and not place undue reliance on such statements. Except as required by law or regulation, Botanix undertakes no obligation to update forward-looking statements.